Literature DB >> 1939162

Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins.

S M Rybak1, S K Saxena, E J Ackerman, R J Youle.   

Abstract

Pancreatic RNase injected into Xenopus oocytes abolishes protein synthesis at concentrations comparable to the toxin ricin yet has no effect on oocyte protein synthesis when added to the extracellular medium. Therefore RNase behaves like a potent toxin when directed into a cell. To explore the cytotoxic potential of RNase toward mammalian cells, bovine pancreatic ribonuclease A was coupled via a disulfide bond to human transferrin or antibodies to the transferrin receptor. The RNase hybrid proteins were cytotoxic to K562 human erythroleukemia cells in vitro with an IC50 around 10(-7) M whereas greater than 10(-5) M native RNase was required to inhibit protein synthesis. Cytotoxicity requires both components of the conjugate since excess transferrin or ribonuclease inhibitors added to the medium protected the cells from the transferrin-RNase toxicity. Compounds that interfere with transferrin receptor cycling and compartmentalization such as ammonium chloride decreased the cytotoxicity of transferrin-RNase. After a dose-dependent lag period inactivation of protein synthesis by transferrin-RNase followed a first-order decay constant. In a clonogenic assay that measures the extent of cell death 1 x 10(-6) M transferrin-RNase killed at least 4 logs or 99.99% of the cells whereas 70 x 10(-6) M RNase was nontoxic. These results show that RNase coupled to a ligand can be cytotoxic. Human ribonucleases coupled to antibodies also may exhibit receptor-mediated toxicities providing a new approach to selective cell killing possibly with less systemic toxicity and importantly less immunogenicity than the currently employed ligand-toxin conjugates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1939162

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  Immobilized pH gradient focusing of alkaline proteins: analysis of the isoform composition of purified human non-secretory ribonucleases from kidney, liver and spleen.

Authors:  E C Coronel; B W Little; J A Alhadeff
Journal:  Biochem J       Date:  1993-12-15       Impact factor: 3.857

2.  RNase inhibition of human immunodeficiency virus infection of H9 cells.

Authors:  R J Youle; Y N Wu; S M Mikulski; K Shogen; R S Hamilton; D Newton; G D'Alessio; M Gravell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

3.  Polyarginine as a multifunctional fusion tag.

Authors:  Stephen M Fuchs; Ronald T Raines
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

Review 4.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

5.  Humanization of immunotoxins.

Authors:  S M Rybak; H R Hoogenboom; H M Meade; J C Raus; D Schwartz; R J Youle
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

Review 6.  Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

Authors:  Thomas J Rutkoski; Ronald T Raines
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

7.  Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform.

Authors:  Thomas Schirrmann; André Frenzel; Lars Linden; Beatrix Stelte-Ludwig; Jörg Willuda; Axel Harrenga; Stefan Dübel; Beate Müller-Tiemann; Mark Trautwein
Journal:  MAbs       Date:  2014-01-15       Impact factor: 5.857

8.  Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.

Authors:  M P Deonarain; A A Epenetos
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

Review 9.  Targeting enzymes for cancer therapy: old enzymes in new roles.

Authors:  M P Deonarain; A A Epenetos
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

10.  Barnase as a new therapeutic agent triggering apoptosis in human cancer cells.

Authors:  Evelina Edelweiss; Taras G Balandin; Julia L Ivanova; Gennady V Lutsenko; Olga G Leonova; Vladimir I Popenko; Alexander M Sapozhnikov; Sergey M Deyev
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.